Mutations in<unk>  are associated with cerebrotendineous xanthomatosis, a rare lipid storage disease. Inhibitors of<unk>  may be effective as adjuvants in the treatment of ER-positive breast cancer due to inhibition of the production of 27-hydroxycholesterol (which has estrogenic actions and stimulates the growth of ER-positive breast cancer cells). Some marketed drugs that have been identified as<unk>  inhibitors include anastrozole, fadrozole, bicalutamide, dexmedetomidine, ravuconazole, and posaconazole.
CYP27A1
CYP1A1
CYP1A2
GcMAF
CYP2C19
CYP3A4
UGT1A4
CYP3A